03 Ene Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size, Industry Share, Trends 2024-34
Market Overview:
The chimeric antigen receptor (CAR) T-cell therapy market reached a value of US$ 3589.7 Million in 2023 and expected to reach US$ 11282.5 Million by 2034, exhibiting a growth rate (CAGR) of 10.85% during 2024-2034. The chimeric antigen receptor (CAR) T-cell therapy market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market’s performance in the seven major regions. Additionally, the report evaluates the performance of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in the report. This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone interested or involved in the chimeric antigen receptor (CAR) T-cell therapy market.
Request for a sample of this Report: https://www.imarcgroup.com/chimeric-antigen-receptor-t-cell-therapy-market/requestsample
Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Trends:
Chimeric antigen receptor (CAR) T-cell therapy represents an innovative form of immunotherapy where T cells are engineered to express receptors targeting specific antigens on cancer cells. The chimeric antigen receptor (CAR) T-cell therapy market is experiencing substantial growth due to the rising burden of cancer, particularly hematologic malignancies such as leukemia and lymphoma. Besides this, the remarkable clinical success of FDA-approved treatments like tisagenlecleucel and axicabtagene ciloleucel is fueling the chimeric antigen receptor (CAR) T-cell therapy market expansion by establishing their efficacy and safety. Continuous advancements in genetic engineering and cell-processing technologies are improving the scalability, precision, and affordability of CAR T-cell production, thus enhancing accessibility.
Moreover, the growing number of clinical trials investigating these therapies for solid tumors and other non-cancerous conditions, such as autoimmune diseases, is extending the therapeutic scope of this technology, thereby boosting the chimeric antigen receptor (CAR) T-cell therapy market growth. Strategic collaborations between biotechnology companies, research institutions, and healthcare providers are fostering the development of next-generation treatments with improved efficacy and reduced toxicity. Additionally, supportive regulatory frameworks, orphan drug designations, and financial incentives for developing innovative cancer cures are attracting significant investment in this sector, further augmenting the chimeric antigen receptor (CAR) T-cell therapy market expansion. Furthermore, the adoption of point-of-care manufacturing and decentralized production models to streamline medical delivery, particularly in underserved regions, is expected to bolster the chimeric antigen receptor (CAR) T-cell therapy market growth in the coming years.
Countries Covered:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country:
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the chimeric antigen receptor (CAR) T-cell therapy market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the chimeric antigen receptor (CAR) T-cell therapy market
- Reimbursement scenario in the market
- In-market and pipeline drugs
This report also provides a detailed analysis of the current chimeric antigen receptor (CAR) T-cell therapy market drugs and late-stage pipeline drugs.
In-Market Drugs:
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
- Drug overview
- Mechanism of action
- Regulatory status
- Clinical trial results
- Drug uptake and market performance
Competitive Landscape with key players:
The competitive landscape of the chimeric antigen receptor (CAR) T-cell therapy market has been studied in the report with the detailed profiles of the key players operating in the market.
Some of these Key Players:
- Juno Therapeutics
- 2seventy bio
- Janssen Biotech
- Novartis
- Kite Pharma
- Novartis Pharmaceuticals
- Tessa Therapeutics
- Cartesian Therapeutics
- Arcellx
Ask Analyst for Customization and Explore Full Report with TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=6383&flag=C
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
Sin comentarios